Next-Generation Bispecific Nanobody Targeting LAG3 and PDCD1 for Innovative Colon Cancer Immunotherapy
VHH-P248 is a fully humanized nanobody therapeutic candidate designed to simultaneously target lymphocyte activating 3 (LAG3) and programmed cell death 1 (PDCD1). Currently in the Biological Testing development phase, VHH-P248 harnesses the latest advancements in bispecific antibody engineering. Its unique structure offers the dual blockade of immune checkpoints, representing a breakthrough approach for the treatment of colon cancer. The innovative molecular design and dual-targeting mechanism suggest the potential for improved clinical outcomes by modulating immune suppression within the tumor microenvironment and enhancing anti-tumor immune responses.
| Candidate | VHH-P248 |
| Target | lymphocyte activating 3 (LAG3) programmed cell death 1 (PDCD1) |
| Modality | humanized bispecific VHH |
| Indication | Colon Cancer |
Licensing Opportunity
VHH-P248 is available for out-licensing and partnership opportunities. We welcome collaboration with industry leaders and investors interested in advancing next-generation immunotherapy for colon cancer.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P248 |
Modality
VHH-P248 utilizes a heterodimeric, bispecific antibody fusion construct composed of three polypeptides. The design leverages engineered nanobodies—single-domain antibodies with small molecular weight—which are recognized for their enhanced tissue penetration and high stability. The anti-PDCD1 component is structured with variable heavy and light chains fused to corresponding constant regions and Fc domains, while the LAG3-targeting part comprises tandem humanized nanobodies with an Fc fusion. This modular and asymmetric structure is produced via re-engineered immunoglobulin technology, enabling optimal engagement of distinct immune checkpoints. The compact nanobody domains facilitate superior tumor infiltration and stability, characteristics especially beneficial for treating solid tumors such as colon cancer.
Target
LAG3 and PDCD1 are pivotal immune checkpoint molecules that modulate T cell responses. LAG3 is a membrane protein expressed primarily on activated T cells, natural killer cells, and some dendritic cells, functioning as a negative regulator of immune activation. PDCD1 is predominantly found on activated T cells and acts to attenuate immune responses upon ligand binding. Both LAG3 and PDCD1 are often co-expressed within the tumor microenvironment in colon cancer, contributing to T cell exhaustion and immune escape. Targeting LAG3 and PDCD1 disrupts this immune suppression, reinvigorating anti-tumor immunity. The dual blockade provided by VHH-P248 establishes a strategic advantage for colon cancer therapy, positioning LAG3 and PDCD1 as highly attractive and complementary immunotherapeutic targets.
Mechanism of Action
VHH-P248 operates as an immune checkpoint inhibitor, binding specifically to both LAG3 and PDCD1 on immune effector cells. By antagonizing these two non-redundant inhibitory pathways, VHH-P248 is designed to unleash suppressed T cells, thereby promoting a more robust and sustained anti-tumor immune response in colon cancer. The bispecific format allows for simultaneous and efficient blockade of multiple immune checkpoints, overcoming compensatory mechanisms that often lead to resistance with monotherapies. This nanobody platform also holds significant promise for future therapeutic modalities, offering the flexibility to be engineered as antibody-drug conjugates (ADCs), multispecific antibodies, or used in combination immunotherapy regimens.
Colon Cancer
Colon cancer is a prevalent malignancy worldwide, ranking among the leading causes of cancer-related morbidity and mortality. It arises from the epithelial cells of the colon or rectum and is often diagnosed at an advanced stage due to the lack of early symptoms. Current standard treatments include surgery, chemotherapy, radiation therapy, and targeted therapies; however, prognosis for advanced or metastatic cases remains poor. While immune checkpoint inhibitors have achieved success in certain settings, many patients exhibit primary or acquired resistance. Thus, there is a critical need for novel immunotherapies capable of overcoming the immunosuppressive tumor environment. By simultaneously targeting LAG3 and PDCD1, VHH-P248 offers a promising strategy to improve response rates and durability of remission in colon cancer, potentially addressing key gaps in current therapeutic approaches.